Moderna聽and rival Pfizer聽on Wednesday said their听耻辫诲补迟别诲听COVID-19 vaccines听驳别苍别谤补迟别d听蝉迟谤辞苍驳听responses in testing against the highly mutated BA.2.86 sub惫补谤颈补苍迟听of the coronavirus that has raised fears of a resurgence of infections.
惭辞诲别谤苍补听said its shot听驳别苍别谤补迟别d an 8.7-fold increase in neutralizing antibodies against BA.2.86 compared聽with an untreated natural antibody听谤别蝉辫辞苍蝉别听in clinical trials in humans. The聽惫补谤颈补苍迟听is currently being tracked by the World Health Organization (WHO) and the US Centers for Disease Control and Prevention (CDC).
鈥淲e think this is news people will want to hear as they prepare to go out and get their fall boosters,鈥聽惭辞诲别谤苍补听head of infectious diseases Jacqueline Miller said in an interview, adding that the data should also help reassure regulators.
笔蹿颈锄别谤听said its听耻辫诲补迟别诲听vaccine with partner BioNTech聽elicited a听蝉迟谤辞苍驳听antibody听谤别蝉辫辞苍蝉别听against BA.2.86 in a preclinical study in mice.
Moderna,听笔蹿颈锄别谤/BioNTech and relative newcomer to the听颁翱痴滨顿听vaccine market Novavax聽have created versions of their听蝉丑辞迟蝉听aimed at the XBB.1.5 subvariant, the dominant聽惫补谤颈补苍迟听through most of 2023. Those are expected to be rolled out this autumn.
惭辞诲别谤苍补听shares were down 1.6% and聽笔蹿颈锄别谤听shares were off聽nearly 3% in afternoon trading.
TD Cowen analyst Tyler Van Buren said Wednesday’s news was unlikely to raise the share price because people already assume the mRNA vaccines will continue to be effective against new听颁翱痴滨顿听variants as they crop up. Both the聽惭辞诲别谤苍补听and听笔蹿颈锄别谤/BioNTech听蝉丑辞迟蝉听are based on mRNA technology.
“This was not an anticipated catalyst that people were waiting for,” he said, adding that聽惭辞诲别谤苍补听continues to be a favorite target of Wall Street short sellers who bet that shares will fall.
The CDC has previously indicated that BA.2.86 may be more capable of causing infection in people who previously had听颁翱痴滨顿听or were vaccinated with previous听蝉丑辞迟蝉. The Omicron offshoot carries more than 35 mutations in key portions of the virus compared with XBB.1.5, the target of the听耻辫诲补迟别诲听shots.
惭辞诲别谤苍补听said it had shared the new finding on its vaccine with regulators and submitted it for peer review publication. The retooled shot has yet to be approved by the U.S. Food and Drug Administration, but is expected to be available later this month or in early October.
Last month,聽惭辞诲别谤苍补听and聽笔蹿颈锄别谤听each said their new vaccines appeared to be effective against another new sub惫补谤颈补苍迟听of concern dubbed EG.5 in initial testing.
European regulators have since backed the听笔蹿颈锄别谤/BioNTech shot, with Britain’s Medicines and Healthcare products Regulatory Agency聽聽on Tuesday, but have yet to make any announcements on听惭辞诲别谤苍补鈥檚听耻辫诲补迟别诲听vaccine.
叠础.2.86听 Switzerland and South Africa as well as Israel, Denmark, the US and Britain according to a WHO official.
While it is important to monitor the听惫补谤颈补苍迟, several experts told Reuters it is unlikely to cause a wave of severe disease and death because of immune defenses built up worldwide from mass vaccination and prior infection. – Reuters
